What is Acerus Pharmaceuticals?
Headquartered in Mississauga, Canada, Acerus Pharmaceuticals Corporation is a specialty pharmaceutical entity dedicated to the development, manufacturing, and commercialization of innovative products targeting men's and women's health. The company's market position is defined by its proprietary delivery technologies, such as the TriVair platform, and a robust product pipeline that includes Natesto for testosterone replacement and Noctiva for the treatment of nocturia.
Beyond its current commercial offerings, Acerus maintains a strong focus on clinical-stage development, including Lidbree and various combination therapies for urological conditions. By integrating internal research and development with strategic distribution partnerships, the company effectively addresses unmet medical needs, positioning itself as a specialized player in the global pharmaceutical landscape.
How much funding has Acerus Pharmaceuticals raised?
Acerus Pharmaceuticals has raised a total of $24.5M across 2 funding rounds:
Debt
$6.5M
Share Placement
$18M
Debt (2019): $6.5M with participation from First Generation Capital
Share Placement (2020): $18M led by First Generation Capital
Key Investors in Acerus Pharmaceuticals
First Generation Capital
FirstGen Capital is a boutique Venture Capital firm providing seed and early stage invest capital to start up businesses in Australia and New Zealand. They focus on backing ventures with the potential to contribute to a socially connected and sustainable future across various technology sectors.
What's next for Acerus Pharmaceuticals?
Looking ahead, the strategic deployment of the $18M will likely focus on scaling the commercial reach of existing assets while advancing the clinical pipeline toward regulatory milestones. The company is expected to prioritize the optimization of its salesforce in North America and the strengthening of its international distribution network to maximize market penetration for its flagship products.
Furthermore, the capital will support the ongoing development of pre-clinical and clinical-stage assets, including treatments for benign prostatic hypertrophy and overactive bladder. As Acerus continues to refine its therapeutic focus, the firm remains committed to leveraging its proprietary delivery systems to secure a competitive advantage in the highly regulated pharmaceutical industry, ensuring sustainable growth and continued innovation in patient care.
